Modulation of the folate receptor type β gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites

Blood

Volumn 101, Issue 11, 2003, Pages 4551-4560

  Hao, Hong ^b   Qi, Huiling ^b   Ratnam, Manohar ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR TYPE B; GLYCOPEPTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN FOS; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL SURFACE RECEPTOR; FOLATE BINDING PROTEIN; FOLATE-BINDING PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SP1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; MONOCYTE; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; TRANSCRIPTION INITIATION; BLOOD CELL; CELL CULTURE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; REGULATOR GENE;

BLOOD CELLS; CARRIER PROTEINS; GENES, REGULATOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, CELL SURFACE; RECEPTORS, RETINOIC ACID; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSFECTION; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0037789606     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3174     Document Type: Article

References (56)

1. Lacey SW, Sanders JM, Rothberg KG, Anderson RG, Kamen BA. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J Clin Invest. 1989;84:715-720.
2. Elwood PC. Molecular cloning and characerization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem. 1989;264:14893-14901.
3. Ratnam M, Marquardt H, Duhring JL, Freisheim JH. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry. 1989;28:8249-8254.
4. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994;33:1209-1215.
5. Luhrs CA, Iomiany BL. A human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol tail. J Biol Chem. 1989; 264:21446-21449.
6. Yan W, Ratnam M. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry. 1995;34:14594-14600.
7. Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995;34:5660-5665.
8. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
9. Buist MR, Molthoff CF, Kenemans P, Meijer CJ. Distribution of OV-TL3 and MOv18 in normal and malignant ovarian tissue. J Clin Pathol. 1995;48: 631-636.
10. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999;8:775-782.
11. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991;51:5329-5338.
12. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer. 1994;73:2432-2443.
13. Weitman SD, Frazier KM, Kamen BA. The folate receptor in central nervous system malignancies of childhood. J Neurooncol. 1994;21:107-112.
14. Ross JF, Wang H, Behm FG, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85:348-357.
15. Nakashima-Matsushita N, Homma T, Yu S, et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:1609-1616.
16. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood. 2002;100:594-602.
17. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today. 2001;6:44-51.
18. Ward CM. Folate-targeted non-viral DNA vectors for cancer gene therapy. Curr Opin Mol Ther. 2000;2:182-187.
19. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000;6:1949-1957.
20. Luiten RM, Warnaar SO, Sanborn D, et al. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother. 1997; 20:496-504.
21. Melani C, Figini M, Nicosia D, et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 1998;58:4146-4154.
22. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol. 1999;163:1923-1928.
23. Peoples GE, Anderson BW, Lee TV, et al. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res. 1999; 5:4214-4223.
24. Wang H, Zheng X, Behm FG, Ratnam M. Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. Blood. 2000;96:3529-3536.
25. Sadasivan E, Cedeno MM, Rothenberg SP. Characterization of the gene encoding a folate-binding protein expressed in human placenta: identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein. J Biol Chem. 1994;269:4725-4735.
26. Wang H, Ross JF, Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type γ/γ′. Nucl Acids Res. 1998;26:2132-2142.
27. Dignam JD, Labovitz RM, Roeder RG, Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res. 1983;11:1475-1489.
28. Boyd KE, Farnham PJ. Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol Cell Biol. 1999;19:8393-8399.
29. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14: 2314-2329.
30. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene Jun/AP-1 by serum and TPA. Nature. 1988;334:629-631.
31. Ryder K, Lan LF, Nathans D. A gene activated by growth factors is related to the oncogene v-jun. Proc Natl Acad Sci U S A. 1988;85:1487-1491.
32. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S. Physical interaction between retinoic acid receptor and sp1: mechanism for induction of urokinase by retinoic acid. Blood. 1999;93:4264-4276.
33. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S. Transactivation via RAR/ RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif. Mol Endocrinol. 2001;15:1677-1692.
34. Pfahl M. Nuclear recepfor/AP-1 interaction. Endocr Rev. 1993;14:651-658.
35. Zhou X-F, Shen X-Q, Shemshedini L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Mol Endocrinol. 1999;13:276-285.
36. Karin M, Zheng-gang L, Ebrahim Z. AP-1 function and regulation. Curr Opin Cell Biol, 1997;9:240-248.
37. Gegonne A, Bosselut R, Bally RA, Ghysdael J. Synergistic activation of the HTLV1 LTR Ets-responsive region by transcription factors Ets1 and Sp1. EMBO J. 1993;12:1169-1178.
38. Chen H-M, Pahl H, Scheiber RJ, Zhang D-E, Tenen DG. The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid-specific promoter activity. J Biol Chem. 1993;268:8230-8239.
39. Dittmer J, Gegonne A, Gitlin S, Ghysdael J, Brandy J. Regulation of parathyroid hormone-related protein (PTHrP) gene expression: Sp1 binds through an inverted CACCC motif and regulates promoter activity in cooperation with Etsl. J Biol Chem. 1994;269:21428-21434.
40. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev. 1999;9:140-147.
41. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940-954.
42. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996; 85:403-414.
43. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition the JNK pathway. Genes Dev. 1997; 11:3351-3364.
44. Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin aging and retinoid antagonism. Nature. 1996;379:335-339.
45. Kaiser A, Brembeck FH, v Marschall Z, Riecken EO, Wiedenmann B, Rosewicz S. Fra-1: a novel target for retinoic action. FEBS Lett. 1999;448:45-48.
46. Jonat C, Rahmsdorf HJ, Park KK, Cato ACB, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62:1189-1204.
47. Yang-Yen H-F, Chambard J-C, Sun Y-L, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutational inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62:1205-1215.
48. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science. 1990;249:1266-1272.
49. Yang Yen H-F, Zhang K, Graupner G, et al. Antagonism between retinoic acid receptors and AP-1: implication for tumor promotion and inflammation. New Biol. 1991;3:1206-1219.
50. Schule R, Rangarajan P, Yang N, et al. Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci U S A. 1991;88:6092-6096.
51. Konig H, Ponta H, Rahmsdorf JH, Herrlich P. Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. EMBO J. 1992;11:2241-2246.
52. Lucibello F, Slater EP, Jooss K, Beato M, Muller R. Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB. EMBO J. 1990;9:2827-2834.
53. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
54. Maxam AM, Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 1980;65:499-560.
55. Ladias JAA, Hadzopoulou-Cladaras M, Kardassis D, et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem. 1992;267:15849-15860.
56. Pikarsky E, Sharir H, Ben-Shushan E, Bergman Y. Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region. Mol Cell Biol. 1994;14:1026-1038.